Coherus Oncology vs Sutro Biopharma
CHRS and STRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CHRS and STRO compare
Sutro Biopharma is the larger company, worth 1.9 times as much as Coherus Oncology ($170M against $90.0M).
Coherus Oncology grew revenue faster over the last twelve months (44.4% versus −56.3% for Sutro Biopharma).
Coherus Oncology keeps more of each dollar of sales as profit, with a net margin of −253% compared with −395% at Sutro Biopharma.
Sutro Biopharma scores higher on the StockData Score (7 against 6 for Coherus Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CHRS | STRO |
|---|---|---|
| Size and price | ||
| Market cap | $90.0M | $170M |
| Share price | $0.583 | $10.26 |
| Change, 1 year | −53.8% | 27.3% |
| Change, 5 years | −96.9% | −94.2% |
| Beta (5Y) | 1.39 | 2.21 |
| Employees | 147 | 137 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 3.7× |
| P/B | 3.6× | – |
| Fair value | $0.870 | – |
| Margin of safety | 33.1% | – |
| Growth | ||
| Revenue growth (TTM) | 44.4% (better) | −56.3% |
| Revenue growth, 5Y average | −38.4% | 19.1% (better) |
| Net income growth (TTM) | −188% | – |
| EPS growth, 5Y average | −2.5% | – |
| Profitability | ||
| Gross margin | 69.8% | – |
| Operating margin | −276% (better) | −320% |
| Net margin | −253% (better) | −395% |
| Return on equity | −241% | – |
| Financial health | ||
| Interest coverage | −15.5× | – |
| Current ratio | 1.51 | 3.32 (better) |
| Altman Z-score | −14.02 | −8.74 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 45.5% | 99.4% |
| Held by insiders | 1.3% | 6.1% |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | 8.3% | 14.5% |
Go deeper
- CHRS stock overview
- CHRS income statement
- CHRS valuation and score
- STRO stock overview
- STRO income statement
- STRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.